7,767 press releases indexed under healthcare.
Dr Charles Garrison, an experienced pathologist, biotechnology entrepreneur, and life sciences investor will advise MVT on scientific and medical development as new Scientific Advisory Board member. [PR.com]
TARRYTOWN, N.Y., Sept. 14, 2026 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing first-in-class peptide therapeutics targeting the underlying oncogenic and immune mechanisms driving cancer and pre-cancerous disease, today...
Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs", being held later today, September 14, 2026Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal...
TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA)...
IND clearance further expands development of C-CAR168 across chronic autoimmune diseases with significant unmet medical need ROCKVILLE, Md. and SHANGHAI, Sept. 14, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company...
IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced U.S. Food and Drug Administration (FDA) clearance of Mint, the Company’s patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. Mint is expected to meaningfully expand the Company’s addressable insulin delivery market, particularly among people with diabetes seeking a patch pump form factor.
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer ( NCT06072612 ).
(PR-inside.com) NEW YORK, NY / ACCESS Newswire / September 14, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against ..
Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Geoff Benic, Chief Executive Officer of Altrova Health, will be presenting on the company's recent milestones and future growth strategy.The ArcStone-Kingswood...
Physician-controlled lab-to-plan workflow, ISSCA protocol ingestion, licensed technology partnership, and clinic-facing SaaS and membership design - with the physician remaining the decision-maker
CAMBRIDGE, Mass., September 14, 2026--Lysoway Therapeutics, a clinical-stage biotechnology company pioneering therapeutics targeting lysosomal ion channels for age-related neurodegenerative diseases, today announced the publication of preclinical data evaluating its lead candidate, LW-1017, in Scientific Reports, a journal from Nature Portfolio.